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Abstract
Chemotherapy-Induced Peripheral Neuropathy Education and Assessment
Kim Schmidt
2015
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of most
chemotherapeutic agents used to treat cancer. To ensure the best possible care and
outcomes for patients, nurses should be at the forefront of CIPN education and patient
assessments. The purpose of this project was to evaluate an educational intervention for
oncology nurses on CIPN and CIPN patient assessment by assessing the knowledge and
confidence level of nurses in assessing CIPN before and after an educational session. The
methodology for this project was a quasi-experimental one-group pretest multiple posttest
design with a convenience sample of nurses employed by the Cancer Center.
Questionnaires with Likert scale measurements for nurses’ confidence and multiple
choice questions for nurses’ knowledge were used to gather data. The mean confidence
level increased from pretest to both posttests, and statistical significance was reached in
the increase in overall confidence. The nurses showed increased knowledge with
statistical significance reached. Further inquiry is suggested with a larger sample size and
a confidence and knowledge test that has been tested for validity.
Keywords: Chemotherapy-induced peripheral neuropathy, neuropathy, nursing
education, nursing knowledge, nursing confidence, oncology nurses, infusion nurses,
cancer, oncology, professional development, nurse continuing education, nurse
assessment.
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Chapter I: Introduction and Background
Introduction
Peripheral neuropathy (PN) occurs because of damage or dysfunction of
peripheral nerves, which can impair motor, sensory, and autonomic function
(Stubblefield et al., 2009). These impairments can lead to decreased quality of life (QoL),
decreased ability to manage activities of daily living, decreased physical abilities, and
possibly decreased life expectancy (Stubblefield et al., 2009). Many chemotherapeutic
agents given to treat cancer can cause PN and most cancer types are treated with
neurotoxic chemotherapy (Hershman et al., 2014; Stubblefield et al., 2009).
Understanding PN and its early detection are imperative for effective management of
chemotherapy-induced peripheral neuropathy (CIPN) (Stubblefield et al., 2009).
Because CIPN is a devastating side effect of many chemotherapy agents, it is
essential for nurses to know how to assess for this complication. Historically, CIPN has
been more commonly discussed with patients because of voluntary reporting and not
clinician query (Stubblefield et al., 2009). Oncology nurses often have a unique
relationship with their patients because of the length of time spent with the patients from
the time of diagnosis, throughout treatment, and follow up. This gives nurses the
opportunity to build a relationship and work closely with patients and conduct thorough
assessments. Oncology nurses believe assessments for CIPN are necessary, but lack the
confidence to perform them (Binner, Ross & Browner, 2011). More education is needed
to enable oncology nurses in performing routine assessments for CIPN in patients
receiving neurotoxic chemotherapies.
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Significance of the Problem
According to the American Cancer Society (2014), there are nearly 14.5 million
cancer survivors in the United States, and this number continues to grow as the aging
population grows. For cancer patients treated with multiple agents, the incidence of
CIPN is approximately 38% (Hershman et al., 2014). Some patients will return to
baseline; however, some patients are never able to improve. Currently, there is no cure
for CIPN. Treatment is primarily focused on pain management. Chemotherapy may be
manipulated through treatment delays or dose reduction to ameliorate CIPN in certain
cases (Stubblefield et al., 2009).
The National Comprehensive Cancer Network (NCCN) guidelines recommend
baseline assessment and continued assessment during treatment, which should include
patient grading assessment, pain assessment, and functional assessment (Stubblefield et
al., 2009). Treatment and referral must be prescribed by the providers, but nurses can
play an integral role in assessing and identifying patients with CIPN. Binner et al. (2011)
found that 75% of nurses studied believed their CIPN assessment skills were fair to poor
and they lacked confidence in their assessment skills. With proper education, nurses
should be appropriately prepared to administer the assessments necessary for CIPN
which may increase the identification of and improve outcomes for patients with CIPN.
Despite no cure or preventive treatment for CIPN, identification by nurses may benefit
the patient through better symptom management and informed decision-making. Patients
are more satisfied with treatment decisions when they feel well-informed (Martinez,
Schwartz, Freres, Fraze, & Hornik, 2009). Early identification and intervention as able
are extremely important; however, there is currently no gold standard for the evaluation
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of CIPN (Stubblefield et al., 2009). The available guidelines on CIPN do not offer gold
standard recommendations on how to educate nurses and assess patients (Hershman et al.,
2014; Stubblefield et al., 2009; Visovsky, Collins, Abbott, Aschenbrenner, & Hart,
2007). The American Society of Clinical Oncology (ASCO) (Hershman et al., 2014) and
Oncology Nursing Society (ONS) (Visovsky et al., 2007) guidelines focus on prevention
and management of CIPN through pharmacologic and nonpharmacologic interventions.
The NCCN guidelines are broader, but still do not suggest a specific protocol for
healthcare provider education or patient assessments (Stubblefield et al., 2009).
Additionally, the assessment and documentation of CIPN in the Cancer Center
was insufficient. The majority of patients treated at the Cancer Center are treated with
neurotoxic chemotherapy, thus putting them at risk for CIPN. There was no formal
process for adequate assessment of patients for CIPN in this clinic. All patients are
queried about their pain level at every appointment; however, a generic query of pain on
a scale of 1-10 is not specific enough for neuropathic pain (Mann, 2008). All cancer
patients are asked to fill out the NCCN Distress Thermometer (Appendix A) prior to each
appointment, which includes questions regarding symptoms experienced such as pain or
tingling in the hands or feet. Albeit useful, this tool is not all encompassing of the aspects
needed to fully assess for CIPN, particularly for function, motor, and sensory. A nursedriven protocol was developed from the ONS PEP card for patients who call in to the
Cancer Center with symptoms of CIPN (Visovsky et al., 2007). However, this protocol
was not successfully implemented and there had been little to no education for the nurses
on this topic. Nurses were requesting more education so they would feel more prepared to
care for patients with CIPN.
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Population of Interest
The population of interest for this project was oncology nurses in a Midwest
outpatient Cancer Center caring for patients who have cancer and receive chemotherapy
known to cause peripheral neuropathy. Oncology nurses are distinct because of the close
contact they have with patients during a vulnerable period in their life. Oncology nurses
often have a very close relationship with patients through which trust and rapport is built
throughout cancer diagnosis, treatment, and follow ups, this allowing for open
communication, education, and higher quality of care (Maxwell, 2013). Nurses that are
educated about side effects and assessment techniques will ensure patients receive the
highest quality care (Maxwell, 2013).
Clinical Question
The aim of this project was to evaluate an educational intervention for oncology
nurses on CIPN and CIPN patient assessment. The clinical question was as follows: What
is the effect of an educational program on oncology nurses knowledge of CIPN and
confidence in assessing patients for CIPN over a three month period of time compared to
baseline knowledge and confidence level? The following expands on the clinical question
of interest in PICOT format.
P: Population of interest. The population of interest was oncology nurses at a
Midwest outpatient Cancer Center that care for patients who receive chemotherapy
known to cause peripheral neuropathy.
I: Intervention of interest. The intervention for this project was an education
session for nurses about CIPN. An educational PowerPoint presentation with handouts
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was presented to the nurses. Nurses were also educated on how to assess patients for
CIPN with hands on demonstrations.
C: Comparison of interest. The project intended to compare nurses’ knowledge
of CIPN and their confidence level with assessing for CIPN, at baseline, immediately
following education, and three months after education.
O: Outcomes of the interest. The intended outcomes for this project were to
increase nurses’ knowledge of CIPN and their confidence level with assessing for CIPN.
T: Time. The project was conducted over a 3 month period of time.
Purpose of the Project
The purpose of this project was to evaluate the knowledge of nurses regarding
CIPN and their confidence level in assessing CIPN before and after an educational
session. Without proper education, nurses may not identify patients with or at risk for
CIPN so they can be properly managed. Nurses who lack knowledge of CIPN and lack
confidence in CIPN assessment may not be able to properly care for patients and give
them the best quality care possible. Without this project, there could have been a
continued lack of understanding of CIPN and decreased confidence level of oncology
nurses regarding CIPN. This could have led to less than ideal care for patients, decreased
QoL, and possibly decreased life expectancy. This project has opened the door for
ongoing projects aimed at increasing the identification, better staging of, and better
management of CIPN.
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Research Questions
The following are the research questions this project intended to answer:
1. What is the effect of an educational program about CIPN on oncology
nurses’ knowledge level?
2.

What is the effect of education and hands on demonstration on nurses’
confidence level in assessing for CIPN in patients?

3. What is the effect of a three month time lapse on the knowledge and
confidence level of nurses in regards to CIPN?
Definitions
Oncology nurses care for patients and families who have or had cancer. The role
of an oncology nurse is to monitor symptoms, educate patients, and advocate for the
patient and family. During cancer treatments, patients may be seen in the office several
times a week, or every few weeks. The oncology nurse may be the only healthcare
provider patients see during some of these visits. Often times cancer survivors are
monitored for years, or even for their lifetime, through which time patients become very
acquainted with the healthcare providers in the Cancer Center.
Infusion nurses are nurses who administer IV medications. In the Cancer Center,
infusion nurses administer several types of chemotherapy, biotherapy, hydration, antiemetics, and many more drugs in an outpatient setting. Infusion nurses are with patients
throughout treatment, which may last from several minutes to several hours. This
provides a unique opportunity to create a relationship with patients.
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Cancer Center refers to the local oncology clinic where the project took place, the
setting. The Cancer Center is an adult outpatient medical oncology center and infusion
center where office visits are conducted and chemotherapy, other infusions, and
injections are administered.
Chemotherapy-induced peripheral neuropathy is a common side effect of some
chemotherapy, known as neurotoxic chemotherapy, caused from damage or dysfunction
of the peripheral nerves. Motor, sensory, and autonomic dysfunction can result from
peripheral neuropathy (Stubblefield et al., 2009). Some of the signs and symptoms of
CIPN include numbness, tingling, pain, gait disturbance, difficulty picking objects up or
holding onto objects, diarrhea, constipation, urinary retention, impotence, and
hypotension. Decreased QoL, disability, and possibly even shorter survival may result
from CIPN. The exact cause of CIPN is not known. CIPN may also be referred to by the
drug of cause- taxane induced peripheral neuropathy, or oxaliplatin induced peripheral
neuropathy.
Neurotoxic chemotherapies are drugs given to patients, most commonly cancer
patients, known to cause neurologic dysfunction, such as CIPN. It is not well-known why
neurotoxic chemotherapies damage peripheral nerves and pathogenesis may vary with the
drug used. Neurotoxic chemotherapies may damage sensory axons, causing deterioration
and dying back of axons and myelin sheaths (Wickham, 2007). Cumulative doses of
neurotoxic chemotherapy seem to cause more CIPN. Common neurotoxic
chemotherapies include taxanes, platinums, vinca alkaloids, bortezomib, and thalidomide
(Stubblefield et al., 2009).
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Educational program for nurses on CIPN included a one-hour class with a
PowerPoint presentation (Appendix B) and discussion conducted by the primary project
lead. Information included in the educational program consisted of neurological
pathophysiology, prevalence of CIPN, signs and symptoms of CIPN, and strategies to
manage CIPN. Nurses were also educated through discussion and hands on
demonstration on how to assess patients for CIPN. Handouts were given to the nurses
covering information on how to assess patients for CIPN. The setting for the educational
program was the Cancer Center break room as there was audiovisual equipment,
adequate seating, and tables. One contact hour of continuing education credit was offered
to participants. The Cancer Center manager applied for and was approved for one contact
hour through the Washington State Nurses Association Continuing Education Approval
& Recognition Program, which is accredited by the American Nurses Credentialing
Center’s Commission on Accreditation.
Confidence is the state of feeling comfortable or the belief in one’s ability to do
something (Merriam-Webster, n.d.). Confidence, or comfort, in performing CIPN
assessments is a subjective measure expressed by each individual nurse, which this
program intended to increase through education and practice.
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Chapter II: Review of Literature and Model of Evidence-Based Care
Introduction
A comprehensive review of available research was performed for current
literature on CIPN assessment recommendations, practice guidelines, nurses’ role in
assessment, and nurses’ knowledge of CIPN. Search engines included CINAHL,
EBSCOHost, Medline, Health Source, and OVID to search articles from 2004-2015 with
combinations of the following terms: “cancer,” “neoplasms,” “oncology,”
“antineoplastic,” “peripheral,” “neuropathy,” “peripheral nervous system,”
“chemotherapy induced peripheral neuropathy,” “screening,” “guideline,” “nursing
knowledge,” “professional development,” “nurse continuing education,” “staff
development,” “competency assessment,” “professional competence,” “nurse
assessment.” Examination of referenced articles also revealed useful literature.
Exclusion criteria included any literature that focused on medication and
interventions alone or were written in a language other than English. The Johns Hopkins
evidence rating scale was used to evaluate the level of evidence in the journal articles
reviewed (Dearholt & Dang, 2012). The Johns Hopkins rating scale was used to
determine the strength and quality of evidence. Strength was rated level one through five:
level one was an experimental study, randomized controlled trial, or a meta-analysis of a
randomized controlled trial; level two was a quasi-experimental study; level three was
non-experimental, qualitative, or meta-synthesis; level four was an article of opinion by
experts based on research such as systematic reviews; level five is opinions not based on
research such as personal experience or clinical expertise.
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The quality of evidence was rated A for high, B for good, and C for low quality or
major flaws. An explanation was given for what qualifies as research, summative
reviews, organizational, and expert opinion within the quality rating. The AGREE II
appraisal tool was used to evaluate the clinical practice guidelines (AGREE, 2014). This
tool is a 23 item questionnaire used to assess the methodological rigor and transparency
of practice guidelines with six domains: scope and purpose, stakeholder involvement,
rigor of development, clarity of presentation, applicability, and editorial independence.
An evidence table is provided in appendix C.
The review of literature suggests that CIPN is under-addressed, knowledge
deficits do exist, and standardized, reliable assessments are needed (Binner et al., 2011;
Kiser, Greer, Wilmoth, Dmochowski, & Naumann, 2010; Mann, 2008; Paice, 2009;
Postma & Heimans, 2000; Stubblefield et al., 2009; Visovsky et al., 2007). Furthermore,
research indicates that CIPN identification is a safety and QoL issue that needs to be
more adequately addressed (Cavaletti et al., 2009; Kiser, et al., 2010; Lavoie Smith,
2013; Mols, et al., 2013; Stubblefield et al., 2009; Tofthagen, 2010). At minimum, the
review of literature strongly supported the need for further research in CIPN and nurses’
roles in assessment of CIPN.
Guideline Development
The NCCN, ASCO, and ONS have all published information on CIPN. Despite
these publications, no specific guidelines, or gold standard, for CIPN assessment have
been established in cancer care. These organizations offer key points to include in CIPN
assessments but do not recommend one specific screening tool. Recommendations
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include active assessment for CIPN on the part of healthcare workers at baseline and
throughout treatment, and standardization of assessment to include objective reports,
neuropathic pain specific scale, functional assessment, and patient questionnaires
(Griffith, Merkies, Hill, & Cornblath, 2010; Stubblefield et al., 2009; Wickham, 2007).
Assessment should include a discussion of symptoms along with a numeric scale
(Hershman et al., 2014).
A usable screening tool must be easy for healthcare workers to use and have
minimal cost (Griffith et al., 2010). Binner et al. (2011) discuss that guidelines should be
developed, but must be efficient and manageable in an already demanding setting.
Cavaletti et al. (2010) broke down the different CIPN measures into four groups: the
common toxicity criteria (CTC) scales, functional assessment tools, QoL tools, and
composite scales. CTC scales include the World Health Organization scale, Eastern
Cooperative Oncology Group scale, National Cancer Institute- Common Toxicity Criteria
(NCI-CTC), and the Ajani scale. Currently, if a scale is used by the providers the NCICTC is used. However, not all providers are grading CIPN. The NCI-CTC is commonly
referred to in drug insert instructions for use, which is one main reason this scale is used.
Functional assessment tools include the Functional Assessment of Cancer
Therapy/Gynecologic Oncology Group- neurotoxicity (FACT/GOG-Ntx), Peripheral
Neuropathy Scale, Oxaliplatin-Associated Neuropathy Questionnaires, Scale for
Chemotherapy-Induced Long Term Neurotoxicity, and the Patient Neurotoxicity
Questionnaire. The only Quality of Life assessment tool specific for CIPN is the
European Organization of Research and Treatment of Cancer QLQ-CIPN20. Composite
scales include the Total Neuropathy Score (TNS) and variants of this scale- TNSr, TNSc.
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The data on all the available tools was limited and not robust (Cavaletti et al.,
2010). The literature recommends combining available tools to cover objective,
functional, sensory, pain, and patient reported assessments (Cavaletti et al., 2010; Griffith
et al., 2010; Stubblefield et al., 2009; Wickham, 2007). While awaiting more research on
CIPN, education for healthcare workers and patients is necessary (Stubblefield et al.,
2009).
Nurses should be at the forefront of CIPN screening with the use of validated
tools (Lavoie Smith, 2013). A study of gynecologic oncologists who screened patients for
CIPN noted a lack of standardization and consistency in grading and reporting of CIPN
by providers (Kiser et al., 2010). These gaps could be mitigated if nurses were leaders in
identifying CIPN. Research shows that oncology nurses should be knowledgeable about
CIPN and play a lead role in educating patients. This may lead to improved QoL and
appropriate treatments for patients. Because oncology nurses have such a vital role in the
assessment and management of CIPN, an algorithm was developed for nursing
(Tofthagen, Visovsky, & Hopgood, 2013). This algorithm was developed from current
literature and clinical expertise and could be utilized by oncology nurses in the outpatient
setting. The basis of this method is to query patients at baseline and with every visit
regarding numbness, tingling, and/or discomfort. Additional assessment is warranted
based on changes from the previous assessment.
Symptom Management and Quality of Life
Patients (n=14) were surveyed regarding neuropathic symptoms experienced
while receiving chemotherapy. Information was gathered on non-painful symptoms,
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painful symptoms, and effects on daily life. The results indicate that there is a vast array
of symptoms that are not always easy to describe (Tofthagen, 2010). The most common
non-painful symptoms included numbness (100%), loss of balance (57%), muscle
weakness (57%), and tingling (50%). More than half (57%) of the patients reported that
symptoms interfere with daily life. The majority (71%) also reported pain; however, the
description of pain varied with the most common responses of burning, muscle aches,
and pins and needles. Of concern, half of the patients surveyed reported falls or injuries
related to reduced sensation.
Not all side effects of chemotherapy and cancer can be completely mitigated, but
great effort must be put towards the best symptom management available as to give
patients the best QoL. A higher number of neuropathy symptoms reported correlates to
worse functional status and lower QoL (Mols et al, 2013). Griffith et al. (2010) believe
CIPN is the primary dose-limiting toxicity for numerous chemotherapeutic agents,
leading to decreased physical functioning and QoL. Pain management and strategies to
maximize physical function must be incorporated into patient care, especially considering
there is no current prevention or treatment options for CIPN (Tofthagen et al., 2013).
Additionally, neuropathic pain is often resistant to typical pain management strategies
(Mann, 2008). Close attention should be given to CIPN to avoid any unnecessary
suffrage in cancer patients.
Patients may not even know they have CIPN. Subtle clinical signs of CIPN, such
as decreased vibratory sense, change in temperature sensations, and pinprick sensation
exist prior to patient reported symptoms and physical disabilities (Lavoie Smith, 2013).
Limited patient awareness of symptom emphasizes the need for clinical assessment for
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early detection of CIPN. Considering that CIPN can be a long lasting side effect of
chemotherapy (Mols et al, 2013; Tofthagen, 2010), the intent of treatment, palliative
versus cure, must be determined as this may help determine the acceptable level of CIPN
and resultant side effects. Patients may tolerate more CIPN if the tradeoff is a disease free
state (Wickham, 2007). Additionally, patients may be reluctant to discuss CIPN due to
fear of dose limitations which may affect overall survival (Paice, 2009). Education of
patients, open discussions with providers, and mutual decision-making can alleviate these
fears. Simply listening to the patients and trusting their concerns is empowering to
patients and breaks down barriers for proper assessment, early detection, and
management (Hershman et al., 2014; Mann, 2008).
Nurses and Education
The literature shows that nurses need more education regarding CIPN, how it
affects patients, and how to screen patients. Binner et al. (2011) indicate that there is a
knowledge gap regarding CIPN, and nurses have low confidence in their ability to
accurately perform CIPN assessments. Only fifteen percent of the nurses in the study
believed they received previous instruction on how to perform an assessment for CIPN
(Binner et al., 2011). Lavoie Smith (2013) believes nurses are aware that CIPN is an issue
for patients, but unaware how to act on this knowledge. Nurses should be educated on
CIPN and should take an active role in assessment and management.
Although comprehensive assessments and diagnosis by nurses are out of the
scope of practice, short and concise assessments, education, and symptom management
are all roles that nurses can undertake (Mann, 2008; Maxwell, 2013; Paice, 2009;
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Wickham, 2007). Therefore, nurses were the ideal modality for education and assessment
for CIPN. Some elements of CIPN assessment are not as widely known by nurses. For
example, nurses generally do not have adequate training on the use of a tuning fork and
assessing muscle strength (Lavoie Smith, Beck & Cohen, 2008). Following specialized
training, oncology nurses could learn to screen for CIPN in patients. Further education
for nurses and research on the accuracy of nurse assessments for CIPN is needed (Lavoie
Smith et al., 2008). Educating nurses can improve the care and outcomes of patients
(Maxwell, 2013).
Nurses are also ideally suited for assessment of patients for CIPN given that they
are the frontline managers of care prior to receiving chemotherapy (Maxwell, 2013).
Nurses must assess patients prior to administration of chemotherapy and report any
concerning findings to the provider. This allows for one last check that may avoid
worsening CIPN due to the administration of neurotoxic chemotherapy.
Gaps in Evidence
Stubblefield et al. (2009) believe CIPN is an under-researched, adverse event
made more difficult by multi-agent chemotherapy regimens, pre-existing conditions, lack
of standardized screening, and inadequate patient education. The NCCN task force also
believes research has focused on treatment response and survival, rather than side effect
issues such as CIPN. The gap in data makes it difficult to define the prevalence of CIPN
(Kiser et al., 2010). Lavoie Smith (2013) notes the incidence of CIPN is somewhere
between eight and 83% in phase III clinical trials with taxane administration, a known
neurotoxic chemotherapy, indicating the prevalence of CIPN is not well established.
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ASCO supports the need for more reliable research with larger sample sizes,
especially given that it was unable to identify consistent or definitive evidence to support
prevention or treatment strategies (Hershman et al., 2014). Evidence-based
recommendations by the ONS regarding CIPN interventions support that there are no
recommended nursing prevention or treatment strategies supported by research (Visovsky
et al., 2007). The ONS believes there needs to be more research with rigor,
standardization, and adequate sample size. In the meantime, nursing interventions of
patient education and support in the following areas are recommended: signs and
symptoms of PN, communication with provider, personal safety, foot care, risk for
ischemia and thermal injury, and management of autonomic dysfunction.
Numerous screening tools have been developed, yet no gold standard exists for
evaluation of CIPN (Stubblefield et al., 2009). There is a great need for more robust
studies on the measurement of CIPN and standardized screening (Griffith et al., 2014;
Hershman et al., 2014; Visovsky et al., 2007). Many articles support CIPN assessments
done by nurses (Binner et al., 2011; Kiser et al., 2010; Lavoie Smith, Cohen, Pett, &
Beck, 2011; Lavoie Smith, 2013; Mann, 2008; Maxwell, 2013; Tofthagen, 2010;
Tofthagen et al., 2013), yet there is little evidence to support that nurses are
knowledgeable and trained to do so (Binner et al., 2011; Lavoie Smith et al., 2008). There
is also minimal research available on how to increase nurses’ confidence in performing
CIPN assessments. Experts agree that CIPN is an issue that needs to be addressed;
however, the practice incorporation of screening is lacking (Binner et al., 2011).
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Implications for Practice
Based on available literature, it is recommended that all oncology nurses receive
training on CIPN. Nurses are educated as generalists to care for all ages and conditions.
Specialties, such as oncology, must train nurses to care for specific populations and
conditions. Training may occur within a practice or through national organizations and
certifying bodies. Because CIPN affects such a large number of patients in the oncology
setting, CIPN-specific training should be offered. This important education was missing
in the education of oncology nurses in the Cancer Center.
It is also recommended that all patients be assessed at baseline, with subsequent
treatments, and with every oncology follow up after receiving neurotoxic chemotherapy.
Nurses should screen patients with an approved tool that is reliable and valid. Because
nurses cannot diagnose or manage CIPN, a notification system should be in place to alert
the providers of the assessment results.
Model of Evidence-Based Care
Clinical practice decisions are not solely based on research, but rather experience
from healthcare workers and patients also contribute to determining best practice. The
combination of research and experience is called evidence-based practice (EBP)
(Dearholt & Dang, 2012). EBP involves improving efficacy, efficiency, and effectiveness
of healthcare while analyzing the risks, benefits and costs. The desire of this project was
to develop an EBP change through the education of nurses on CIPN to improve the care
and outcomes of oncology patients. As indicated in the literature review, the available
research is somewhat limited for this topic. However, the expert opinions presented
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within the research do support the need for identification of CIPN and for nurses to
perform the assessment (Binner et al., 2011; Kiser et al., 2010; Lavoie Smith et al., 2011;
Lavoie Smith, 2013; Mann, 2008; Maxwell, 2013; Tofthagen, 2010; Tofthagen et al.,
2013). The providers within the Cancer Center of interest also desire the implementation
of this project. Therefore, the combination of the available literature on CIPN and a
desire to improve care are the basis for this EBP change.
The Iowa Model of Evidence-Based Practice was used to guide this innovation
project. This model was chosen because of its widely recognized use by healthcare
organizations in the process of implementing EBP changes to improve healthcare
outcomes. The Iowa model was comprised of a series of trigger questions. These trigger
questions follow a stepwise approach to determine the relevance to an organization, if
there is research evidence to support a practice change, if a pilot change is appropriate,
practice wide change, and continued monitoring of outcomes (Burns & Grove, 2005, p.
626-631). This model was also well suited for the evaluation of knowledge, abilities, and
attitudes of those involved in EBP changes. Nurses desire the highest quality of care for
patients, but believe they need more education and time to convert evidence into practice
(Brown, 2014). The Iowa model’s stepwise approach can be used by nurses to implement
EBP changes (Figure 1). This project was merely the beginning steps in the
implementation of EBP change.
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Figure 1. The Iowa Model of Evidence-Based Practice to Promote Quality Care. by Titler
et al., 2001. Reprinted with permission from the University of Iowa Hospitals and Clinics
and Marita G. Titler, PhD, RN, FAAN. Copyright 1998.
The first step of the Iowa Model was to identify the problem. In this project the
problem was a perceived knowledge deficit regarding CIPN and the lack of formal
assessment of patients for CIPN. The second step was to determine the priority level of
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the problem. This project was considered moderate priority because the risk for not
implementing this change was fairly low, yet the desire to provide the best care for
patients was high.
Identifying the team was the next step. Team members for this project included
one certified nurse practitioner (CNP), two nurse managers, the clinic director, and a
South Dakota State University (SDSU) faculty advisor. All team members expressed a
desire to implement this project. A PICOT question was formed, a literature review was
done, and desired outcomes were identified. The paucity of research did not deter the
team. The level of available evidence was relatively low, but the project was still
justified, as it was believed that this project was low risk but could offer great benefits to
the patients and the Cancer Center.
The next step in the Iowa model was to perform a pretest of nursing knowledge
and confidence. Nursing education on CIPN and patient assessment took place and a
posttest was performed. Nurses were then considered trained and expected to assess
patients for CIPN. The project underwent continuous evaluation with changes as needed.
After three months an additional nursing knowledge and confidence posttest was
performed, along with project evaluation. At this point it will be determined if formal
assessment for CIPN should be developed and implemented. Dissemination of the results
will take place for possible CIPN assessment organization wide and possibly in other
cancer centers.
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Adult Learning Theory
This innovation project proposed to educate nurses about CIPN so proper
identification of CIPN can take place for patients receiving neurotoxic chemotherapy.
The Adult Learning Theory was used to guide this project. Adult learning, or andragogy,
was studied by Malcolm Knowles who believed there are five underlying assumptions:
adult learners are independent and self-directed, life experiences influence learning,
social roles and learning are related, adult learners are interested in applicable and
problem-focused learning, and adults have internal motivations for learning (Merriam,
2002). Additionally, Knowles developed four principles of andragogy (Figure 2). These
include the need to be involved in the education process, incorporation of the learner’s
previous experiences, relevance and impact on the learner, and problem-centered
education.
To be in alignment with these assumptions and principles, the educational session
was offered at two different times and simple options were given to the learners for
independence in style of learning- handouts and writing tools, visual PowerPoints, and
discussions. This will help to foster respect, support, and autonomy in learning (Merriam,
2002). Open communication and dialogue with the nurses was used to promote approval.
The nurses’ previous knowledge was gathered through a pre-test and was used to form
the educational session to build on. Evaluations were done in the form of a posttest,
which nurses were able to review. For the nurses to relate the importance of the
education, background information and impact on patients was given to the nurses. The
hope was that if nurses could see the impact this education and identification of CIPN
could make on patients, they would more likely to adapt to the change. Also, the
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immediate application of knowledge through CIPN assessments should help in the
adaptation to change.

Figure 2. Malcolm Knowles Adult Learning Theory. Reprinted from “The Adult
Learning Theory- Andaragogy- of Malcolm Knowles” by C. Pappas, 2013, from
http://elearningindustry.com/the-adult-learning-theory-andragogy-of-malcolm-knowles.
Reprinted with permission.
Change Theory
In 1962, Everett Rogers published his first book on the change theory, Diffusion
of Innovation. Since then, the theory has been used around the world with numerous
disciplines and countless innovative projects. From the time new research is unveiled or a
new process is developed, it can take years to spread the information for the benefit of
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others (Rogers, 1995). One reason the theory is widely known is because it aims to
improve the time it takes to disperse the knowledge of an innovative change.
Diffusion is the process of communicating new ideas to others in a group in order
to make mutual decision (Rogers, 1995). This change theory is applicable because the
aim of this project was designed to deliver knowledge about CIPN and the need for
identification of patients in order to improve care for patients. CIPN education and
assessment for nurses is a new idea in the Cancer Center given there is a perceived
knowledge deficit and lack of formal assessment.
Roger’s (1995) four components were used in this project: innovation,
communication, time, and social system. Nurses in the Cancer Center were educated on
CIPN and assessments which was anticipated to improve the knowledge of nurses.
Knowledge was retested after three months to test for retention, knowledge gaps, and
confidence. This project is expected to contribute to the innovation-decision making for
future formal implementation of assessment of patients for CIPN.
The rate of adoption by the nurses is an important factor for the long term success
of CIPN assessments. It was anticipated that the innovators would be influential team
members. A desire to provide better care to patients and continuing education contact
hours were expected to influence the nurses in the early adopters and early majority
categories. The late majority and laggards (Rogers, 1995) may have needed more time to
accept the knowledge and see the need to identify patients with CIPN. The majority of
the nurses who adopted the change helped encourage the late majority and laggards and
continue the process of educating these nurses.
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Chapter III: Project Design and Methodology
Introduction
EBP is the incorporation of best available research, practitioner experiences, and
patient needs into high quality and cost-conscious care (Burns & Grove, 2005). EBP is
essential for improving healthcare and patient outcomes. This EBP change was intended
to increase the knowledge and confidence of nurses in their care of patients with, or at
risk for, CIPN. It has the potential to improve the care and outcomes of patients who
receive known neurotoxic chemotherapy agents.
Population
The population studied was a convenience sample of nurses employed in an
outpatient Cancer Center in a large Midwest city. The Cancer Center contains a clinic
where provider office visits are conducted and an infusion center where treatments are
given. At the time of the project initiation there were 10 nurses that primarily worked in
chemotherapy infusions, and 10 nurses that worked primarily in the providers’ offices.
Several of these nurses have cross training to both areas. There are also four CNPs
employed by the Cancer Center that care for patients in the clinic, infusion center, and
hospital. All nurses had some college level education, between two to six years of
college. Approximately half of the nurses were oncology certified and
chemotherapy/biotherapy certified. Years of nursing experience ranged from 0-20 years.
Most of the nurses worked full time. The majority of the nurses were Caucasian.
According to the 2010 census, the state in which the Cancer Center is located is
84.7% Caucasian (United States Census Bureau, 2014). Additional races served include
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African American, American Indian, Hispanic, and Asian. The percentage of persons 25
years or older who are a high school graduate or higher is 90.1%, while those with a
bachelor’s degree or higher is 26%.
Setting
The setting for this project was the Cancer Center- an adult outpatient medical
oncology center and infusion center in a large Midwest city which serves a large
geographic region, including urban, rural, and frontier population. Demographics of
patients at this clinic were primarily Caucasian, middle class, and 18 years old and older.
The center included six oncologists, four CNPs, four pharmacists, and multiple other
support staff. Services offered within the Cancer Center included doctors’ offices, cancer
treatment administration, pharmacy, lab, palliative care, psychiatry, and research studies.
This project was well suited for this Cancer Center because no standard existed in this
clinic for CIPN assessments, and providers expressed a desire to implement a formal
assessment process.
Design
This practice innovation project was a quasi-experimental one-group pretest
multiple posttest design. Questionnaires with multiple choice questions were used to
gather the pre and posttest data (Appendix D). The pre and posttests were identical.
Advantages of the one group pretest multiple posttest design included identification of
baseline knowledge, as well as comparison of pre and post-education knowledge (Burns
& Grove, 2005). The simple structure and simple analysis of data was also an advantage
to this design. Disadvantages include maturation from pretest to posttest not attributable
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to the education, no comparison group or independent variable, and the lack of
generalizability (Burns & Grove, 2005).
Participant Recruitment
Participants were recruited from nurses and CNPs who worked at the oncology
center. Approximately two weeks before the education, the project leader emailed all
nurses with an overview of the project, including timeline, objectives, and contact
information. One week prior to the education, fliers were hung in the break room and an
email was sent to all nurses from a Cancer Center manager which included the date,
times, objectives of the education, and contact hour information. Two sessions were
offered, one at 7:30 am and one at 4:30 pm, to optimize nurses’ ability to attend. These
scheduled times were the standard format for nursing education in the Cancer Center.
Participation in the project was not be mandatory, but was be highly encouraged. One
contact hour was given to nurses who attend the educational session. A Cancer Center
manager completed the application process for the contact hours and approval was
received.
Development of Education
Education content was compiled from available literature and clinical expertise.
No standardized education content or format for nurses on CIPN existed at the time of
this project. Content for education included pathophysiology, significance, associated
factors, prevention, management, methods for assessment, and patient education.
Additional emphasis was given during the education based on the pretest results to ensure
deficient areas were well discussed. Education on performing CIPN patient assessment
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was also done through discussion and hands on demonstrations. The CIPN patient
assessment consisted of already existing resources, based on clinic preference, and ease
of assessment for the nurses. Education format was based on the common format of
education for the clinic. Handouts were given to the nurses containing step by step
information on the CIPN patient assessment process. The four principles of the Adult
Learning Theory (Merriam, 2002) helped guide the education format development by
involving the nurses in the education process, incorporating nurses’ baseline knowledge
and experience of CIPN, identifying why this education is relevant, and identifying CIPN
as a problem while working towards improving patient care.
Intervention
The intervention was an educational session for nurses on CIPN and CIPN
identification. Nursing knowledge and confidence was tested. A pretest was administered
to nurses to determine baseline knowledge of CIPN and their confidence in performing a
patient assessment for CIPN. Gaps in knowledge that were identified from the pretest
were incorporated into and emphasized in a one hour educational session on CIPN.
Nurses were also taught how to identify patients with CIPN through PowerPoint
discussion and hands on learning. The education was in the form of a PowerPoint
presentation, discussion, and demonstration. Following the education, nurses were again
tested on their knowledge and confidence to compare from baseline before the education.
An additional posttest was administered three months after the initial education. This
posttest served as a measure of knowledge retention and change in confidence.
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Instruments
Demographic information was obtained at the time of the pretest (Appendix E).
No standardized tests for nursing knowledge on CIPN existed at the time. The pretest and
posttest were identical and were developed from available literature and clinical expertise
(Appendix D). Nurses’ confidence in identifying CIPN was also measured in the pretest
and posttests. CIPN signs and symptoms, common patient reports, common causes, and
treatments were included in the tests, which supports the content validity of the tests
because of the broad range of knowledge tested on CIPN. Face validity was tested with
four inpatient oncology nurses not directly involved with this project, and their
conclusion was that the pre and posttests were at least adequate for measuring nursing
knowledge and confidence. Reliability was established through review of the pretest and
posttest by a provider highly knowledgeable in CIPN. It was not feasible to fully test
validity and reliability prior to the start of this project due to time constraints and
resources available.
At the time of the project, the Cancer Center was not interested in implementing
additional screening instruments in full. The Cancer Center implemented the Distress
Thermometer (Appendix A) in March of 2014, and it was felt that the available
functional assessments were too lengthy and contained duplicate questions. The
institution agreed to pull the neurotoxicity questions from the FACT/GOG-Ntx
(Appendix F) and add these with the Distress Thermometer, which are both selfadministered screenings. The Cancer Center believed combining the Distress
Thermometer with neuropathy specific questions from the FACT/GOG-Ntx (Appendix
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F), a thorough pain assessment, and simple function and sensory testing was adequate
and appropriate based on the evidence reviewed.
Following review of available literature and published guidelines, a simple five
component assessment was compiled. The five components included patient self-report,
quality of life screening, sensory testing, functional testing, and a clinical grading system.
The Distress Thermometer and the FACT/GOG-Ntx was to be given to all cancer patients
at registration to fill out independently. Nurses were to record the self-administered
screening results in the electronic medical record (EMR). Pain assessments will continue
to be recorded as before, with additional emphasis on neuropathic pain. Sensory testing
was to be done with two point discrimination using a paperclip. Functional testing was to
be done by asking each patient to pick up a small paperclip from a flat surface. This
information was to be recorded in the EMR in a progress note for the visit which was to
be used to communicate to the provider. With the information gathered, the hope was that
the providers who saw the patient could easily assign a clinical grade, specifically the
NCI-CTCAE, to each patient. The assessment process was modified throughout the
project to better accommodate the nurses and providers, and to better assess the patients.
Modifications are discussed in chapter four.
Education for nurses was the essential first step to CIPN assessments so the
nurses better understood CIPN, the importance of identification, and how to administer
an assessment. Nurse education was step one in the process of improving care for patients
with CIPN. This project positions the Cancer Center for further research and EBP in
patient assessments for CIPN conducted by nurses.
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Protection of Human Subjects
Approval from the SDSU Human Subjects Committee was obtained (Appendix
G), as well as the Institutional Review Board of the organization where the project took
place (Appendix H). Written approval from the Cancer Center director and the Chief
Nurse Executive was obtained prior to initiation of this project. Consent of the
participating nurses was implied by their voluntary participation. Results from nursing
demographics and testing were kept secure at all times. This project was considered low
risk with potential important benefits for nurses and patients. No patient data was
obtained or analyzed for this project.
Project Analysis
Different measures were used to analyze the data collected. Questions one
through five were Likert scale format. T-tests were used to test the mean scores and
determine if there is a significant difference between the pretest and posttests with
statistical significance set at 0.05 (Burns & Grove, 2005). One-way ANOVA was used to
test the difference between the means of the pretest and posttests (Burns & Grove, 2005).
Questions six through 23 were knowledge questions; the averages of the scores correct
pre and posttest were recorded and analyzed. Descriptive statistics were used to analyze
demographic data. Demographic information on the participating nurses was gathered,
including the following information: age, gender, ethnicity, education, employment
status, primary work area, years of nursing experience, years of oncology experience,
oncology certification, chemotherapy and biotherapy certification, and previous formal
training on CIPN.
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Environmental and Organizational Context
Nurses are expected to be able to assess and identify adverse symptoms from
cancer and chemotherapy. Education is offered on a regular basis in the Cancer Center
for nurses on types of cancer, medications, and symptom management. Prior to this
project education had never been offered specifically on CIPN, which made this project
novel and significant for this clinic.
Assessment tools available for nurses in the Cancer Center that may be applicable
to CIPN include a pain assessment flow sheet, the NCCN Distress Thermometer, and a
nurse-driven triage protocol on neuropathy. These assessment tools do not allow for
thorough assessment of CIPN. Additionally, no education or formal implementation of
the nurse-driven triage protocol has been conducted since development. The areas
missing from the assessment tools prior to this project were function, motor, and sensory
assessment. To properly assess for CIPN, a better focused assessment incorporating
available tools, missing assessment areas, and compilation of information in one place in
the EMR should be developed, educated on, and implemented. This project paves the
way for a future CIPN screening protocol.
This project was also important to the Cancer Center because there was no current
standardized education for patients regarding CIPN. Patients are given informational
handouts developed by the National Institute of Health entitled Managing Chemotherapy
Side Effects: Nerve Changes, and Managing Chemotherapy Side Effects: Pain on their
first day of chemotherapy if they receive a neurotoxic chemotherapy. Given the perceived
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nurses’ knowledge deficit and lack of standardized patient education, this project will
help nurses be prepared to educate patients.
The Cancer Center is dedicated to exceptional care, research, and advancing the
care of cancer patients. This project aligns with these values because it has the potential
to improve the care through education of nurses and research based interventions. The
clinic administration was supportive of this project as they seek to increase education of
nurses and to improve the care of patients. Patients also desire improved symptom
management and care. Healthcare is competitive and patients will seek out the best care
available.
Stakeholders and Facilitators
Key stakeholders of this project within the healthcare system included physicians,
CNPs, nurses, and management from the Cancer Center. Patients and families were also
stakeholders as they serve to benefit from the education and process change within the
clinic related to improved identification of CIPN. This should translate into improved
care and outcomes for patients.
One CNP was identified as the primary facilitator who helped form the
committee, advocate for the project, and develop the nursing education and testing. She
had a strong interest and extensive education in symptom management. All of the
providers at the Cancer Center expressed an interest and support of the project.
Management and nurses also expressed their desire to support and assist in this project.
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Anticipated Barriers
Anticipated barriers included resistance from nurses who may not perceive value
in the education and assessment of CIPN due to the time involved. While research
indicates that nurses desire to EBP changes and improved care for patients, lack of time is
frequently cited as a barrier to EBP change (Melnyk, Fineout-Overholt, Gallagher-Ford,
& Kaplan, 2012). Sustainability of the assessments following the education was also a
perceived barrier, primarily related to nurses’ resistance. Lack of support from leadership
may also be a barrier to EBP implementation (Melnyk et al., 2012), which could directly
affect nursing time and sustainability. If the Cancer Center leadership is not supportive
and does not allow nurses to take the time to become more educated or to assess patients,
this project will not be sustainable.
With an already small sample size, nurses who chose not to participate in the
project were a perceived barrier to interpretation of the results. Attempts to overcome
these barriers were made through nurse input, contact hours credit for the education, and
positive reinforcement from the project leader and stakeholder. The education, itself, was
a means to break the barriers as it intended to educate nurses on the prevalence of CIPN
and the quality of life concerns for patients.
With the lack of concrete recommendations from guidelines, choosing an
assessment method was a barrier. It was important for the nurses and providers to come
to a consensus on what assessment components to use and how to communicate the
results to the providers. Additionally, having the screening tool in the EMR would have
been ideal for ease of data input, comparing from assessment to assessment, and
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interpretation by the providers. This was not realistic or feasible prior to the project
implementation. Historically, it can be difficult and time consuming to have changes
made to the EMR charting formats. Although this wasn’t necessarily a barrier to the
implementation of education, it did prevent ideal compilation of assessment results. EMR
documentation will be an area to focus on in the sustainability process. For the purpose of
this project, a “dot phrase” template was created for data input into the chart and entered
into a progress note in the patient encounter.
Organizational Impact
This project has the potential of positively financially impacting the organization.
Nurses who are better educated can provide better care. Patients whose symptoms are
well managed may have lower healthcare costs. Patient satisfaction scores may also be
impacted if patients feel they are receiving better care. Patient satisfaction is increasingly
being measured and reported publicly, and may impact reimbursement.
Policy implementation based on research and EBP is vital to healthcare. Through
the literature identified in this project and the results of the nurse education, a novel CIPN
assessment strategy process could be developed. These patient assessments may
positively impact patients through early identification of CIPN so proper management
can take place. This project may open the door to further policy implementation of CIPN
screening, which can be modified with future literature recommendations.
Rural and underserved patients are treated on a daily basis in this Cancer Center.
The region the Cancer Center serves is primarily rural. Geriatric patients were one
underserved population that was impacted by CIPN assessment and identification.
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Approximately 46% of cancer survivors are older than 70 years of age (American Cancer
Society, 2014). Cancer survivors are living longer and the elderly population is growing.
With cancer patients living longer, and the need to care for a larger elderly population, it
is important to provide the best possible, evidence-based, care to these patients to prevent
years of unnecessary suffering.
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Chapter IV: Results and Analysis
Introduction
The population studied was a convenience sample of nurses employed by the
Cancer Center who voluntarily participated in education on CIPN and were asked to
complete a pretest and two posttests. The pretest was distributed to all nurses in the
Cancer Center one week prior to the education session. Nurses were allowed to turn in
the pretests up until the time of the education. The posttest was distributed at the
completion of the education program, handed out with the contact hours. The second
posttest was distributed three months after the education session to all nurses who
attended the education session. Pretests returned with demographics totaled 20, with 16
first posttests, and 12 second posttests returned.
Demographics
Of the 20 demographic surveys that were returned, 11 worked primarily in the
clinic and nine worked primarily in the infusion center. The mean age surveyed was 32.2.
Ninety percent surveyed were female and all identified as Caucasian. All nurses have
some college level education: two certificates, eight associates, six bachelors, four
masters or higher (Figure 3). Seventeen nurses surveyed were full-time employees and
three were part-time. The majority of the nurses had between three and 11 years of
nursing experience and less than six years of oncology experience (Figure 4). Nineteen
nurses were chemotherapy/biotherapy certified and 10 were Oncology Certified Nurses.
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All nurses surveyed marked that they had never had previous formal training on CIPN.
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Figure 3. Education level of nurse participants.
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Figure 4. Years of experience of nurse participants.
Project Outcomes
Nursing knowledge. The range of correct answers on the pretest was 10 to 17 out
of 18 questions with a mean score of 13.7 (SD 2.05). The range of correct answers on the
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first posttest was 13 to 18 with a mean score of 16 (SD 1.55). The range of correct
answers on the second posttest was 10 to 17 with a mean score of 15.33 (SD 1.78) (Table
1). The improvement in scores was statistically significant from the pretest to the first
posttest (p<0.01), and from the pretest to the second posttest (p= 0.025) (Table 2). There
was a statistically significant difference between the groups as determined by one-way
ANOVA (F(2,45)=7.515, p<0.01) (Table 3).
Table 1
Knowledge Mean and Standard Deviation
Range
Mean
Pretest
10-17
13.7
st
1 Posttest
13-18
16
2nd Posttest
10-17
15.3

Standard Deviation
2.05
1.55
1.78

Table 2
Knowledge Statistical Significance
T value
Pretest and 1st Posttest
-3.82774
Pretest and 2nd Posttest
-2.37319
st
nd
1 Posttest and 2 Posttest 1.03784

p value
0.000529
0.025312
0.310618

Table 3
ANOVA
Between
Within
Total

SS
50.027
150.737
200.764

Df
2
45
47

MS
7.467
3.350

F
7.467

P
0.002

Confidence. Confidence in nurses’ knowledge and ability was assessed on a
Likert scale with five being very confident, three was somewhat confident, and one was
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not confident at all. The range of confidence on the pretest was 1.5 to 4. The range of
confidence on the first posttest was 1 to 5 and 3 to 5 on the second posttest. The mean
confidence level on the pretest was 2.94, first posttest was 4.00, and second posttest was
4.13. Individual confidence increased with each test except for one nurse who initially
marked 1-2 on the pretest for confidence in ability to perform CIPN assessment and
marked 1 on the first posttest. No second posttest was received for this nurse. This was
the only nurse that marked 1 for confidence. Statistical significance was reached in the
increase in overall confidence from the pretest to the second posttest (p= 0.0457) (Table 4
and Table 5).
Table 4
Confidence Range and Mean
Range
Pretest
1.5-4
st
1 Posttest
1-5
2nd Posttest
3-5

Mean
2.94
4
4.13

Standard Deviation
0.80
0.80
0.54

Table 5
Confidence Statistical Significance
T value
Pretest and 1st Posttest
-6.17382
nd
Pretest and 2 Posttest
-4.51567
1st Posttest and 2nd Posttest
-0.57324

p value
0.102228
0.045705
0.668633

Application of knowledge. Additional questions were included in the test in
Likert scale format from one to five in regards to how important the nurses felt CIPN
assessments were, how often assessments were being done, and the likelihood of
performing CIPN assessments. The means for importance were 4.65 pretest, 4.27 first
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posttest, and 4.58 second posttest. The means for frequency of assessments for the
pretest, first posttest, and second posttest were 3.74, 4, and 3.67 respectively. The means
for likelihood of assessing patients were 4 pretest, 4.56 first posttest, and 4.25 second
posttest (Table 6). One nurse had marked on the pretest that CIPN assessments were done
on every patient and subsequently marked on the first posttest “I don’t know how to
assess CIPN.” A second posttest was not completed by this nurse.
Table 6
Application Mean
Pretest
1st Posttest
2nd Posttest

Importance
4.65
3.74
4

Frequency
4.27
4
4.56

Likelihood
4.58
3.67
4.25

Anecdotal information. Nurses were queried with both posttests if they felt their
knowledge had increased since the time of the education and all answered either
somewhat or definitely. Nurse managers and providers approached the project leader with
information that they had noticed an increase in identification of CIPN by nurses. The
nurses also had positive feedback to the managers about the knowledge they gained with
comments such as “I’m glad I know the chemotherapy medications better now,” and “I
had no idea that certain disease put a person at higher risk for neuropathy.” During
discussions about continuation or modification of CIPN assessments by nurses one nurse
stated “Even if we can identify one person with neuropathy we’ve made a difference.
There is value in assessing all chemotherapy patients for CIPN.”
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Chapter V: Discussion of Outcomes
Discussion
The purpose of this project was to evaluate effect of an educational program on
the knowledge of oncology nurses regarding CIPN and their confidence level with
assessing CIPN before and after an educational session. The PICOT question and the
clinical questions were answered with this project. The effect of education and hands on
demonstration was that there was an increase in knowledge and confidence. Following
the education session nurses expressed an increase in knowledge about CIPN and
confidence in assessing patients for CIPN. The three month timeframe from the education
to the second posttest was attributable to very little loss in knowledge and marginal
increase in confidence. The overall increase in knowledge and confidence indicates
nurses’ ability to provide better care and identify CIPN earlier. Interpretation of results
from pretest to the second posttest was made difficult by a 40% decrease in response rate.
There was a positive effect on nursing knowledge of CIPN from baseline to the
three month posttest. There was an increase in knowledge from baseline to the first
posttest and baseline to the second posttest. There was statistical significance in the
increase in knowledge for both pretest to first posttest and pretest to second posttest. The
content and presentation of the education on CIPN was in a format that was easy to
understand and gain knowledge from. The format of the education eased access and
encouraged attendance. The contact hours were a positive incentive for education
attendance. There was a slight loss in knowledge from the first posttest to the second
posttest with mean scores decreasing from 16 to 15.33 respectively. Loss of knowledge
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could be attributed to regression and the time from education to the second posttest.
Distribution of notes with key education points or distribution of the PowerPoint itself
may have provided access for a knowledge refresher as nurses felt the need. This could
be considered as an option for future education.
There was a positive effect on nursing confidence in assessing patients for CIPN
from baseline to the three month posttest. While not statistically significant, the mean
score for overall confidence from pretest to first posttest did increase. It’s possible that
nurses needed more hands on experience with assessments prior to feeling confident.
This is evident in the statistically significant increase in confidence from pretest to the
second posttest. An increase in awareness of the need for assessment may also be
attributed to the increase in confidence.
The results of this project support the available literature in finding that nurses do
not receive adequate training on CIPN. Despite the fact that all but one nurse had
chemotherapy-biotherapy training, and half were Oncology Certified Nurses, none had
received formal training on CIPN. This project also supports the literature in recognizing
that CIPN is important and that nurses can be taught how to perform assessments. While
not formally evaluated, nurses did express to the project leader agreement with literature
that for sustainability any assessment of CIPN by nurses has to be fairly simple and quick
to perform.
The results are also in alignment with previous literature in that prior to CIPN
specific education, nurses are not overly confident in their knowledge or ability to assess
patients for CIPN. Nurses do not get adequate training for specialty assessments during
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nursing school. On the job education and training for medical specialties is needed to
supplement the nursing school general education. To become confident in specialty
assessments, nurses need to perform multiple assessments over a period of time. This
project was important to educate nurses about CIPN and instruct them on how to identify
those at risk for and those who currently have CIPN. Routine education on CIPN should
take place in the Cancer Center, as well as other oncology areas, so that nurses are more
knowledgeable and confident in their assessments of patients.
Reflections
Evidence-based care is a constantly evolving process. There was an increase in
nursing knowledge and confidence, and there were beneficial modifications to the patient
assessment process; however, further education and process refinement needs to be done.
According to the Iowa Model, this project is not ready for adoption. Further evaluation of
the quality of care given and new research as it becomes available should be incorporated
into another pilot project on nursing knowledge, confidence in assessments, and patient
assessments of CIPN.
The Adult Learning Theory was, indeed, helpful in this project (Merriam, 2002).
The nurse learners were actively involved in their own education and they were given a
choice to be involved. Some lead nurses were increasingly involved in modification and
sustainment of the patient assessment portion, thus providing autonomy and ownership in
the process. The education was developed based on what the nurses already knew and
was expanded beyond the baseline while incorporating old and new skills. Nurses agreed
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that assessing CIPN was important, which therefore, endorsed the relevance and impact
on the learner, and problem-centered education.
The Diffusion of Innovation theory (Rogers, 1995) has helped and will continue
to help the progress of this project. By continuing to communicate ways to improve
nursing education and patient assessments, this small scale project can be perfected in a
shorter time in order to be applicable on a larger scale. This supportive social system
within the Cancer Center is conducive to innovative decision making.
The significance of the problem was addressed by increasing the knowledge of
nurses so they are better prepared to identify and care for patients with CIPN. One area of
knowledge that was improved upon was autonomic nervous system dysfunction
symptoms, such as hypotension, shortness of breath, impotence, and constipation. Not
only did knowledge increase from pretest to posttest in these areas, nurses expressed to
the project leader that they are more aware of symptoms of CIPN and are better able to
identify patients who may have CIPN. It is reasonable to presume that the increase in
nurses’ knowledge may improve care provided to vulnerable cancer patients.
This project adds to the under-addressed, under-researched issue of CIPN by
identifying a means to improve awareness and care for patients. With proper specialized
education, oncology nurses can gain an increase in knowledge on CIPN and an increase
in confidence to assess and identify patients at risk for, and with CIPN. Because of this
project, there was an increase in knowledge and confidence about CIPN in nurses in the
Cancer Center.
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Limitations
Possibly the greatest limitation to interpretation of the results was attrition. There
was a 20% response reduction from pretest to the first posttest and a 40% response
reduction from the pretest to the second posttest. The reason for this was multifactorial.
Around the time of the initiation of this project there were significant staffing changes in
the clinic and infusion center. The clinic had been short staffed which may have
increased nurse resistance to buy in to a project that did take time and effort. Shortly after
project initiation the clinic had an influx of very novice nurses just out of nursing school.
This may have made sustainability of patient assessments difficult because of the lack of
knowledge. These new nurses were just honing basic nursing skills and may not have
been ready to learn new, potentially more advanced skills. Perhaps specialty orientation
should occur three to six months after employment.
Attrition is a risk in any post-survey. Methods used to prevent a high attrition rate
included distribution of contact information for the project leader with an open invitation
to contact with questions at any time, regular face to face contact with managers and
nursing staff, and email reminders to fill out and return the posttests. Additional methods
to prevent attrition that could have been considered would include an incentive to turn in
posttests and additional contact information gathered at the time of the initial test.
Furthermore, offering an online testing option may have been more convenient and
appealing to nurses and could be used in the future. Nursing resistance was not evident in
the initial pretest and education; however, it likely contributed to attrition of posttests and
sustainability of the patient assessment.
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Discussions between the clinic and infusion center on where and when the
assessment should take place occurred, as each area thought it would be best done in the
other area. A clearer protocol enforced by nursing management with defined
reassessment of the protocol, perhaps a month after initiation, may have improved
acceptance and sustainability.
Time could have been a factor in completing the posttests. While the tests were
short, it still was an added task in what nurses perceived as an already busy day. Staffing
issues contributed to the lack of nursing downtime. Assessment of the patient was felt to
be time consuming, particularly by the clinic nurses. It would be expected to have slower
assessment times and frustrations at initiation of a new process. Positive reinforcement
was given; however, more time may still have been needed to allow for adjustment to the
process. While initially perceived as beneficial to initiate patient assessments by nurses
immediately following the education, perhaps the resistance to the process change caused
resistance to the education posttests. Separating CIPN education and patient assessments
with a period of time, perhaps one to two months, may also improve resistance.
Additionally, a project dedicated to the evaluation of CIPN assessments would be
warranted allowing a project leader more involvement and focus on this process alone.
Lack of concrete recommendations on nursing education, nursing knowledge
assessment, and patient assessment posed a barrier. While there was an increase in
knowledge, as evidenced by statistically significant increase in correct answers from
pretest to posttests, the validity of the test is unknown. Face validity was performed;
however, further evaluation should be done to show if the questions are adequate to test
nursing knowledge. Lack of concrete recommendations on how patients should be
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assessed continues to be a barrier because the clinic would like to improve patient
assessments but were somewhat unsuccessful immediately following this project.
Recommendations for Practice
Based on the increased knowledge level and confidence in assessment, it would
be recommended to implement education on CIPN for all nursing staff. One
recommendation extrapolated from this project would be to have education at regular
intervals. While the Cancer Center does have educational sessions once or twice a month,
which are an hour long and often very in depth topics, it was discussed that perhaps
smaller topics could be educated on in a shorter format, perhaps a PowerPoint
presentation emailed to all the nurses to be read at their convenience with an independent
posttest for knowledge evaluation. CIPN, for example, could be discussed once or twice a
year as a refresher. Staffing changes can also be addressed with this format. Just in the
time of this project’s implementation, there were multiple new nurses who started in the
Cancer Center. Continual rotation of important topics, such as CIPN, throughout the year
may improve knowledge deficits and improve care for patients in this specialty
population. This continual rotation of education can address research and EBP changes as
well.
Prior to project initiation, providers expressed a desire to better assess patients for
CIPN. Little feedback was given on what exactly was desired content for the
assessments. There was a perceived lack of provider acknowledgement of the information
obtained by the nurses, which caused frustration on behalf of the nurses. For future
modifications of the CIPN patient assessments, more information could be gathered from
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the providers on what worked, what didn’t work, and recommendations for nursing
practice change.
Recommendations for Future Projects
Recommendations for future projects include means of improving cancer patients’
symptoms and QoL, specifically in regards to CIPN. While research has made great gains
in addressing common symptoms from cancer and chemotherapy such as nausea and
neutropenia, more research needs to be done in the area of CIPN. More research needs to
be done to determine the best format and content for nursing education on CIPN. More
research is also needed to determine the most usable, efficient method for nurses to assess
for CIPN in an outpatient clinic.
Future research should be aimed at validating the best format and content for
nursing education on CIPN. Further inquiry is also suggested with a larger sample size of
nurses and a confidence and knowledge test that has been tested for validity. More
research is also needed to determine the most usable, efficient method for nurses to assess
for CIPN in an outpatient clinic. Additional EBP projects on CIPN are needed to improve
the care and outcomes of cancer patients.
Conclusion
CIPN can be debilitating, decrease QoL, and possibly even decrease the life of
cancer patients who have received neurotoxic chemotherapy (Stubblefield et al., 2009).
Nurses are well suited to make a positive impact on the way we care for patients with or
at risk for CIPN. Despite the fact that there is no gold standard for CIPN nursing
education and patient assessments, and much more research needs to be done on this
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topic, this EBP project successfully educated nurses and increased their confidence in
CIPN. Further inquiry is suggested with a larger sample size and a confidence and
knowledge test that has been tested for validity.
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Appendix A
NCCN Distress Thermometer for Patients

Retrieved from
http://www.nccn.org/patients/resources/life_with_cancer/pdf/nccn_distress_thermometer.pdf
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Appendix B
Nursing Education PowerPoint

What is CIPN?
 Damage to axons, myelin sheaths, or cell bodies
 Adverse Effect of Neurotoxic Chemotherapy

 Peripheral Nervous System is more sensitive to
neurotoxic chemotherapy
 Usually starts distally- toes, fingertips

 Stocking-glove distribution
 Axons may repair when chemotherapy stopped

57

CIPN EDUCATION AND ASSESSMENT

58

CIPN EDUCATION AND ASSESSMENT

59

CIPN EDUCATION AND ASSESSMENT

60

CIPN EDUCATION AND ASSESSMENT

61

Appendix C
Evidence Table
Article First Author,
#
Date, & Title

Evidence
type

1

Crosssectional
exploratory

Binner, Ross,
& Brownder,
2011
Chemotherap
y-Induced
Peripheral
Neuropathy:
Assessment of
Oncology
Nurses’
Knowledge
and Practice

2

Tofthagen,
Visovsky, &
Hopgood
(2013)

Literature
review, EBP
Algorithm
recommendati

Sample,
Sample Size &
Setting
39 oncology
nurses from 2
hospital-based
outpatient
chemo clinics;
convenience
sample

NA

Study findings that help
answer the EBP question

Limitations

Nurses believe CIPN
assessment is important and is
a problem; Nurses are not
confident in their CIPN
assessment skills; Knowledge
deficits exist for non-pharm
management strategies,
autonomic neuropathy as a
form of PN (hypotension), med
term for CIPN sensations; 15%
of nurses received previous
instruction on how to perform
assessment for CIPN; barriers
include limited proficiency,
time, cumbersome
documentation; 33% screen for
baseline PN; practice
integration is lacking
An algorithm developed to be
used by nurses in multiple care
settings; researched and
clinical expertise developed;

Self-selected sample;
survey structure may
have led to promptsnot necessarily
completely accurate;
applicability to other
practices

Not research backedvalidated

Evidence
level &
Quality
Level IIIAB

Level VA
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on

3

Chemotherap
y-Induced
Peripheral
Neuropathy:
An Algorithm
to Guide
Nursing
Management
Mann, 2008
Neuropathic
pain: could
nurses
become more
involved?

4

Mols, et al.,
2013
Chemotherap
y-Induced
Neuropathy
and Its
Association
With Quality
of Life

list of nursing interventions;
describes how to perform
assessments

Literature
review/editori
al

NA

Descriptive
comparative
and
prevalence

1643 patients
diagnosed with
colorectal
cancer
identified
through a
cancer registry;
convenience
sample

Nurse assessment and
management of neuropathic
pain is a viable option in this
under-addressed medical
concern; personal contact time
is essential in identifying
symptoms early which in turn
potentially initiates and
effectively manages treatment;
nurses have this time and
ability; nurses can help with
non-pharm interventions
Patients with multiple
neuropathy symptoms report
lower QOL; CRC patients
continue to report neuropathy
symptoms

Some literature
support- significant
amount of opinion

Level VB

Limited data on
previous use of the
EORTC QLQCIPN20;
comorbidities were
difficult to account
for; no baseline
assessment prior to
treatment; self-report
of PN- no clinical

Level III B
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Among 2- to
11-Year
Colorectal
Cancer
Survivors:
Results From
the
PopulationBased
PROFILES
Registry
5

6

Tofthagen,
2010
Patient
Perceptions
Associated
With
Chemotherap
y-Induced
Peripheral
Neuropathy
Lavoie Smith,
2103
Current
Methods for
the
Assessment
and

assessment; chemo
dosage not known;
causal association
between CIPN and
HRQOL not
determined; not
randomized study

Qualitative;
purposive
convenience
sample

14 cancer
patients who
have received
certain chemos
in an outpatient
clinic setting

Discusses importance of
patient-reported symptoms;
importance of subjective and
objective measures; CIPN
negatively affects QOL; proper
management of CIPN is
important for patient safetyfalls; thorough and frequent
exams by nurses can improve
patient QOL

Literature
review

NA

Oncology nurses are aware PN
is an issue, but not sure what to
do about it; TNS and
FACT/GOG-Ntx; good table
of measurement tools;
“validated assessment tools
should be administered …
prior to each taxane

Small sample size;
Level IIIB
demographics not
necessarily
generalizable; bias r/t
researcher = provider;
lapse of time from tx
completion to study;
no objective or
systematic
assessment
Level VA-B
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Management
of TaxaneRelated
Neuropathy

7

R. Wickham
2007
Chemotherap
y-Induced
Peripheral
Neuropathy:
A Review and
Implications
for Oncology
Nursing
Practice

Literature
review

NA

treatment”; “provides practical
suggestions for how nurses can
take the lead in improving
TIPN measurement practices”;
good discussion on what to
look for/how to evaluate, good
use of case examples
Good article for review of
CIPN including
pathophysiology; Good
description of peripheral nerve
pathophys and why they are
sensitive to certain
chemotherapies; PN are more
sensitive than central nerves;
need better patient education;
incidence of CIPN is unknown,
more common w/ vincristine,
taxanes, and platinums; CIPN
likely to increase r/t longer life
expectancy and more
neurotoxic agents; good tables
with neurotoxic chemos and
grading scales, and nursing
care; online resources;
objective finding of screening
must include functional
impairment; CIPN may be
bothersome but tolerable if
cure is intent, whereas
palliative chemo may have

Level VA-B
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8

Paice, 2009

65

Literature
review

NA

Literature
review

NA

Clinical
challenges:
Chemotherap
y-induced
peripheral
neuropathy

9

Postma &
Heimans,
2000
Grading of
chemotherapy
-induced
peripheral
neuropathy

lower threshold;
comprehensive assessment
impractical for nurses, can
identify patients at risk and
perform brief assessments
Managing CIPN is
challenging; will become more
common with more
chemotherapy agents and
longer survival; prevalence is
unknown because it is not well
studied; no standardized
assessment or staging system;
self-report the most common
method of evaluation, not
systematic; table of validated
tools;
Not an overly helpful article;
lists some grading scales;
recommends standardized
grading scale plus QOL;
limited indications for EP
studies; assess during and after
chemo administration

Level VB

Age- 2000

Level IVBC
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10

Visovsky,
Collins,
Abbott,
Aschenbrenne
r, & Hart,
2007

66

Evidencebased review

NA

Observational
descriptive
with
retrospective
review

171gynecologic
oncology
patients who
received
chemotherapy,
convenience
sample

Putting
evidence into
practice:
Evidencebased
interventions
for
chemotherapy
-induced
peripheral
neuropathy

11

Kiser, Greer,
Wilmoth,
Dmochowski,
& Naumann,
2010
Peripheral
Neuropathy in
Patients With
Gynecologic
Cancer

Incidence unknown r/t no
standardized measurement;
concerning issue because of
need for dose reductions,
treatment delays, or
termination of treatment; no
meta-analyses found for
prevention or treatment; no
recommended/research
supported nursing
interventions for prevention or
treatment; no pharmacologic or
non-pharmacologic
interventions were rigorously
supported; need studies with
more rigor, standardization and
adequate sample size; only
recommendations that can be
made are for education and
support
No standardized grading of PN
or self-reporting of PN exists;
EP scores have little value as
they do not correlate with
patient subjective symptoms;
having received neurotoxic
chemo previously seems to
decrease reporting of
neuropathy in subsequent
treatments; gaps in provider
charting and grading;

Level IV A

Retrospective
analysis, convenience
sample, low
completion rate, gaps
in data, no labeling
on data as to order of
treatment

Level IIIB
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Receiving
Chemotherap
y:
Patient
Reports and
Provider
Assessments

12

13

Maxwell,
2013
Quality-ofLife
Consideration
s With
Taxane-Based
Therapy in
Metastatic
Breast
Cancer:
A Case
Vignette
Lavoie Smith,
Beck &
Cohen, 2008
The Total
Neuropathy

Case vignette

NA

Systematic
review

NA

impossible to determine true
prevalence of CIPN because of
data gaps; Nurses should be
leaders in identifying CIPN
and its effects on QOL;
oncology nurses must be
knowledgeable about CIPN
and educate patients; nurses
play a crucial role in ensuring
patients have good QOL and
appropriate treatment
Infusion nurses are first line
defense as they administer
chemo; nurses don’t have the
time to do proper CIPN
assessments; initial and
continued nursing assessments
and education are important;
teach patients to report
symptoms; nurses are
“frontline managers of
supportive care”

Nerve conduction studies are
considered gold standard, yet
they are expensive, time
consuming, and do not
correlate well with subjective
reports; 3 challenges- nerve

Level V B

Level IV B
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Score: A Tool
for Measuring
Chemotherap
y-Induced
Peripheral
Neuropathy

14

Stubblefield
et al., 2009
NCCN Task
Force Report:
management
of neuropathy
in Cancer

Task force
report/guideli
ne

NA

pain is not always reported
with routine pain assessments;
CIPN is difficult to describe;
oncologists don’t see CIPN as
being a big concern;
appropriate tool has not been
developed yet; TNS is most
comprehensive; should be
considered for use by oncology
nurses; assessments should
include patient distress r/t
CIPN; no literature to support
screening by nurses, but TNS
could easily be taught to nurses
to use; need more research
regarding nurses ability to
accurately assess
Ideal resource for definitions
and signs and symptoms; list
of cancer related causes of PN;
CIPN is the most widely
reported PN in cancer patients;
diagnostic features unique to
CIPN; CIPN is recognized as
an adverse event but not the
focus of studies as response or
survival is; multi-agent
therapies make studying
difficult; pre-existing
conditions as a study
limitation; evaluation based on

Level IVA
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15

Hershman et
al., 2014

Practice
Guideline

69

NA

self-report rather than active
probing; need better teaching
on pain terms and associated
conditions; “quality
assessment and reporting
leading to accurate diagnosis is
a crucial step that must precede
clinical decisions regarding
treatment”; no gold standard
for evaluation of CIPN; current
assessments include clinical
evaluation (grading systems),
objective testing, and
questionnaires; CIPN is
subjective which makes
evaluation more complex; poor
correlation between subjective
and objective data; patient
tolerance and patient
preference influence
interventions; the task force
strongly encourages active
assessment at baseline and
intermittently during therapy;
recommends use of a
neuropathic pain specific scale;
education is necessary in
interim while more studies are
done on treatment
Overall, well written guideline;
it is limited in that there is

Agree II
score of 7
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limited reliable data; bottom
line is there needs to be more
high quality research done; no
consistent or conclusive
evidence that prevention or
treatment strategies work;
communication between
provider and patient are
important for identification and
management; need discussion
along with numeric scale

ASCO

16

Prevention
and
management
of
chemotherapy
induced
peripheral
neuropathy in
survivors of
adult cancers:
American
society of
clinical
oncology
practice
guideline
Griffith et al.,
2014
Evaluation of
chemotherapy
-induced
peripheral
neuropathy
using current
perception
threshold and
clinical

Prospective
observational
pilot study

29 chemo-naïve
cancer patients
who will
receive taxane
or platinum
chemo in an
outpatient
cancer center;
convenience
sample

Patients were studied prior to
chemo and with each cycle;
used NCI-CTCAE v3.0;
measured CPT, QST, and
mechanical sensation of right
great toe; measured grip
strength of dominant hand and
DTR of rightankle; subjective
questionnaires- neuropathic
pain scale, FACT/GOG-ntx;
increased CPT readings may
predict impending reduction in

Relatively small
sample size, subject
heterogeneity,
multiple examinersdifferent
interpretations, need
more robust measure
of CIPN

Level IIIAB
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evaluations

17

Lavoie Smith,
Cohen, Pett,
& Beck 2011

Crosssectional

117 cancer
patients in 2
outpatient
cancer centers;
convenience
sample

Systematic
review

NA

The Validity
of Neuropathy
and
Neuropathic
Pain
Measures in
Patients With
Cancer
Receiving
Taxanes
and Platinums

18

Griffith,
Merkies, Hill,
& Cornblath,
2010
Measures of
chemotherapy
-induced

QOL; NCI-CTCAE score is
associated with CPT 2000impairment and hypoesthesias
occur together; CPT 2000 is a
feasible tool to use for
screening CIPN patients
TNSr-SF and NPS-CIN took 5
mins to complete; TNSr-SF
was simpler to use than TNSr;
reflexes should be measured
but don’t need to be included
in the TNS; the TNSr-SF used
in combination
with the NPS-CIN is preferred
over the NCI-CTC; nurses
should find the TNSr-SF and
NPS-CIN the easiest of all
measures to use within busy
clinical settings; nursephysician collaboration will
lead to better patient care and
patient outcomes, detect subtle
changes, more timely care
Systematic review of validity,
reliability, and responsiveness
of CIPN measures; best tool
must have subjective and
objective measures; must be
easy to use and minimal cost;
FACT/GOG-Tnx and TNS
clinical version are most

Relatively small
sample size; limited
available research

Level IIIB

Level IV AB
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peripheral
neuropathy: a
systematic
review of
psychometric
properties
Cavaletti et
al., 2010
Chemotherap
y-Induced
Peripheral
Neurotoxicity
assessment:
A critical
revision of the
currently
available tools

72

promising

Nonsystematic
review

NA

Reviews several CIPN
evaluation tools; existing
scales are not satisfactory
(rationale delineated with each
scale review); providers
underestimate and underreport
CIPN severity; TNSc and a
reliable QOL questionnaire
(EORTC QLQ-CIPN20) and
pain assessment are most
effective until better screening
is developed

Non-systematic

Level VB
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Appendix D
Pretest and Posttests
1. How confident are you in your knowledge about chemotherapy-induced
peripheral neuropathy (CIPN)? (Please circle a number)
Very confident
5

Somewhat confident
4

3

Not confident at all
2

1

2. How confident are you in your ability to perform an assessment for CIPN?
Very confident
5

Somewhat confident
4

3

Not confident at all
2

1

3. How important do you believe it is to assess for CIPN?
Very important
5

Somewhat important
4

3

Not important at all
2

1

4. How often are you assessing for CIPN?
Every patient
CIPN
5

Just patients at risk
4

3

I don’t know how to assess
2

1

5. What is the likelihood of performing a CIPN assessment on patients if
implemented in the clinic?
Very likely
5

Somewhat likely
4

3

Not likely at all
2

1

6. CIPN can cause persistent pain.
a. True
b. False
7. CIPN can decrease patient’s ability to perform ADLs.
a. True
b. False
8. Which of the following are signs or symptoms of CIPN? (may choose multiple)
a. Numbness or tingling
b. Pain
c. Constipation
d. Temperature intolerance
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9. Which of the following are signs or symptoms of CIPN? (may choose multiple)
a. Hypotension
b. Gait disturbance
c. Shortness of breath
d. Impotence
10. Patients often use this/these terms to describe CIPN. (may choose multiple)
a. I feel like I’m always wearing gloves
b. I can’t feel the heel of my foot
c. I can’t pick up my pills from the counter
d. The pain is hard to describe
11. When assessing for pain, which of the following descriptions may indicate CIPN?
a. Sharp
b. Dull
c. Burning
d. All of the above
12. It is important to assess for proprioception. Why?
a. This will indicate if a patient is safe to drink water
b. Patients with good proprioception should have their blood pressure
monitored closely
c. Patients with poor proprioception may need to walk with a cane and
remove throw rugs from the house
d. Patients with proprioception have frequent diarrhea
13. Which medication is NOT known for causing neuropathy?
a. Rituxan
b. Taxol
c. Carboplatin
d. Thalidomide
14. Which of these assessment findings may indicate CIPN?
a. Patient walks straight down the hallway without assistance
b. Decreased reflexes
c. Heart rate of 90, regular rhythm
d. A negative Romberg test
15. Which information is NOT important at baseline to determine CIPN risk?
a. Alcohol use
b. Charcot-Marie-Tooth disease
c. Diabetes
d. Acetaminophen use
16. Which term is NOT associated with CIPN side effects?
a. Allodynia
b. Dysesthesia
c. Hyperreflexia
d. Paresthesia
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17. Which vinca alkaloid is MOST likely to cause CIPN?
a. Vinblastine
b. Vincristine
c. Vindestine
d. Vinorelbine
18. CIPN always improves after cessation of chemotherapy.
a. True
b. False
19. If a patient has not experienced CIPN before the last dose of cisplatin, they will
not experience CIPN.
a. True
b. False
20. Which medication is most known to cause acute-transient CIPN?
a. Cisplatin
b. Thalidomide
c. Oxaliplatin
d. Docetaxel
21. Which of the following treatments do NCCN and ASCO support for use in
preventing CIPN?
a. Vitamin E
b. Calcium and magnesium infusion
c. Alpha lipoic acid
d. None of the above
22. According to ASCO, which medication is most research supported for the
treatment of CIPN?
a. Nortriptyline
b. Venlafaxine
c. Gabapentin
d. Topical baclofen
23. Which non-medication treatment may have benefit for patients with CIPN?
a. Physical therapy
b. Acupuncture
c. TENS therapy
d. All of the above

75

CIPN EDUCATION AND ASSESSMENT
Appendix E
Demographics Form
1. What is your age?________
2. What is your gender?
a. Female
b. Male
3. What is your ethnicity
a. White
b. Hispanic or Latino
c. Black or African American
d. Native American or American Indian
e. Asian or Pacific Islander
f. Other
4. What is your highest nursing education level?
a. Certificate
b. Associates
c. Bachelors
d. Masters or higher
5. What is your FTE status?
a. Full time
b. Part time
6. Which area do you primarily work in?
a. Clinic
b. Infusion
7. How many years have you been a nurse?
a. 0-2
b. 3-5
c. 6-8
d. 9-11
e. 12-14
f. 15 or more
8. How many years have you been an oncology nurse?
a. 0-2
b. 3-5
c. 6-8
d. 9-11
e. 12-14
f. 15 or more
9. Which of the following certifications do you have? (May choose both)
a. OCN
b. Chemotherapy & biotherapy
10. Have you ever had formal training on Chemotherapy induced peripheral
neuropathy?
a. Yes
b. No
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Appendix F
FACT/GOG-Ntx
Not
at all

A little Some
bit
-what

Quite
a bit

Very much

I have numbness or tingling in my hands ................................
0

1

2

3

4

I have numbness or tingling in my feet ...................................
0

1

2

3

4

I feel discomfort in my hands ..................................................
0

1

2

3

4

I feel discomfort in my feet .....................................................
0

1

2

3

4

I have joint pain or muscle cramps ..........................................
0

1

2

3

4

I feel weak all over ..................................................................
0

1

2

3

4

I have trouble hearing ..............................................................
0

1

2

3

4

I get a ringing or buzzing in my ears .......................................
0

1

2

3

4

I have trouble buttoning buttons ..............................................
0

1

2

3

4

I have trouble feeling the shape of small objects when
they are in my hand .................................................................
0

1

2

3

4

I have trouble walking .............................................................
0

1

2

3

4
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Appendix G
South Dakota State University Institutional Review Board Approval
SDSU IRB
Dec 29, 2014
Kim,
Thanks for the update. I believe that they would likely rule this activity as “not human
subjects research,” possibly exempt human subjects research.
I am going to rule the activity to be “not human subjects research.” With this
determination, no other involvement of the SDSU IRB is required on your part. Please
let me know the determination Sanford makes, to complete our records.

Thanks!
Norm
Norman O. Braaten, PhD, CPIA
Research Compliance Coordinator
South Dakota State University
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Appendix H
Sanford Institutional Review Board Approval
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